Abstracts tagged "Inflammation"

Abstract Number: 0939 • ACR Convergence 2024
A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis
Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…
Abstract Number: 1478 • ACR Convergence 2024
Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
Xenofon Baraliakos¹, Paul Bird², Atul Deodhar³, Dafna Gladman⁴, Philip S. Helliwell⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, Mikkel Ostergaard⁸, Enrique R. Soriano⁹, Lai-shan Tam¹⁰, Soumya Chakravarty¹¹, Evan Leibowitz¹², Cinty Gong¹³, Stephen Xu¹⁴, Thomas Fuerst¹⁵, Nadeem Saeed¹⁶, Robert Landewé¹⁷ and Philip Mease¹⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of New South Wales, Randwick, NSW, Sydney, New South Wales, Australia, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California San Diego, La Jolla, CA, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰The Chinese University of Hong Kong, New Territories, Hong Kong, ¹¹Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ¹²Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ¹³Janssen Scientific Affairs, Horsham, PA, ¹⁴Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁵Clario, San Mateo, CA, ¹⁶Clario, San Mateo, ¹⁷Amsterdam University Medical Center, Meerssen, Netherlands, ¹⁸Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with PsA can develop axial inflammation in the SI joints (SIJs) and/or spine. Although validated classification criteria for axial spondyloarthritis exist, established…
Abstract Number: 1795 • ACR Convergence 2024
Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
Ting Wang¹, Runa Kuley², Payton Hermanson², Gundula Min-oo³, Natasha Crellin⁴, Ching Shang³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³Gilead Sciences, Foster City, CA, ⁴Gilead, Foster City, CA
Background/Purpose: Neutrophil activation has been implicated to contribute to the systemic lupus erythematosus (SLE) pathogenesis. However, factors and mechanisms promoting neutrophil activation in SLE have…
Abstract Number: 2003 • ACR Convergence 2024
Cumulative Incidence of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in Lung Cancer Patients with and Without Hip Osteoarthritis and Impacts on Survival
Laura Cappelli¹, Shadpour Demehri¹, Joseph Murray¹, Julie Brahmer¹, Elena Ghotbi¹, Durrant Barasa¹, Clifton Bingham² and Ami Shah³, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Rheumatologists are increasingly called upon to manage patients with inflammatory arthritis (IA) due to immune checkpoint inhibitor (ICI) therapy. The pathogenesis of ICI-IA is…
Abstract Number: 2531 • ACR Convergence 2024
CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation
Alisa Mueller¹, Suppawat Kongthong², Angela Zou³, Gerald Watts⁴, Cassandra Murphy², Hung Nguyen², Jacqueline Perrigoue⁵, Mathew Chamberlain⁵, Kevin Wei⁶, Soumya Raychaudhuri² and Michael Brenner⁷, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Brookline, MA, ⁵Johnson & Johnson, Spring House, PA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts adopt an inflammatory phenotype that catalyzes pathogenic synovial hyperplasia and ultimately bone and cartilage destruction. However, identifying therapeutic…
Abstract Number: 0089 • ACR Convergence 2024
Single-Cell RNA Sequencing Outlines the Mechanisms of Vgll3-Driven Myofibroblasts Differentiation in Promoting Fibrosis in Cutaneous Lupus
Mehrnaz Gharaee-Kermani, Allison Billi, Poulami Dey, Jacob Martens, Marisa Hildebrandt, J. Michelle Kahlenberg and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling. Some subtypes of cutaneous lupus erythematosus (CLE), particularly discoid lupus erythematosus…
Abstract Number: 0494 • ACR Convergence 2024
Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Ventura Mejia², guillermo velarde² and Graciela Alarcon³, ¹Hncase, Arequipa, Peru, ²UNIVERSIDAD NACIONAL DE SAN AGUSTIN, arequipa, Peru, ³The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) causes systemic inflammation that leads to specific changes in the patients’ blood cells; this offers the opportunity to measure inflammatory activity…
Abstract Number: 0833 • ACR Convergence 2024
Novel Loss of Function Variants in the Death Domain of Tumor Necrosis Factor Superfamily Receptor 1A (TNFRSF1A) in Children with Systemic Juvenile Idiopathic Arthritis (sJIA)
Anthony Cruz¹, Hiroto Nakano², Sophia Chou³, Marissa Krantz⁴, Tianmin Fu⁵, Davide Randazzo⁶, Zuoming deng⁷, Hao Wu⁸ and Michael Ombrello⁹, and INCHARGE Consortium, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³National Institutes of Health, Rockville, MD, ⁴University of Rochester, Rochester, NY, ⁵Ohio State University College of Medicine, Columbus, OH, ⁶NIAMS/NIH, Bethesda, MD, ⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁸Harvard Medical School, Boston, MA, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an inflammatory condition characterized by recurring fevers, arthritis and hyperinflammation, but its exact etiology is unknown. Tumor necrosis…
Abstract Number: 0944 • ACR Convergence 2024
Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy
Melanie Couturier¹, Francis Bonnefoy², emilie Gaiffe³, Charline Vauchy⁴, Suzanne Behlke², ERIC TOUSSIROT⁵ and Sylvain Perruche², ¹1MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ²MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ³INSERM CIC -1431 CHU Besançon, France, Besançon, France, ⁴INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, ⁵university hospital of BESANCON, besancon, France
Background/Purpose: Impaired macrophage efferocytosis, a key hallmark of failed inflammation resolution, is reported in many immune-mediated inflammatory diseases, including in Rheumatoid Arthritis (RA). Hence the…
Abstract Number: 1512 • ACR Convergence 2024
Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: The systemic immune-inflammation index (SII) has been linked to inflammatory and immune responses, with research indicating its impact on rheumatoid arthritis (RA). However, its…
Abstract Number: 1799 • ACR Convergence 2024
In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Jia Xin Chow¹, Rochelle Sherlock², Taylah Bennett², Eric Morand³ and Sarah Jones², ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Australia, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
Abstract Number: 2010 • ACR Convergence 2024
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Austin Wheeler¹, Tanner Ourada², Michael Duryee¹, Bryant England¹, Richard Reynolds³, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and is associated with substantial cardiometabolic morbidity and mortality. In the STOP Gout trial (O’Dell JR…
Abstract Number: 2536 • ACR Convergence 2024
Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Adam Cantor¹, Alba Boix-Amoros³, Jose Scher⁴ and Jose Clemente¹, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
Abstract Number: 0147 • ACR Convergence 2024
Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Mary Jeffway¹, Feng Liu¹, Nancy Shadick¹, Michael Weinblatt², Brittany Weber³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
Abstract Number: 0515 • ACR Convergence 2024
Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis
Olivia Posey, Anastasiia Phothisane, Phicharmon Kulapatana and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Neutrophils contribute to the innate immune response of killing pathogens through the formation of neutrophil extracellular traps (NETs), which is also called NETosis. NETosis…

« Previous Page
1
…
7
8
9
10
11
…
58
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].